We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+91.23%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$735M
AUM Growth
+$18.1M
Cap. Flow
+$54.1M
Cap. Flow %
7.36%
Top 10 Hldgs %
42.08%
Holding
212
New
67
Increased
34
Reduced
65
Closed
41

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$11.6M
2
TGTX icon
TG Therapeutics
TGTX
+$8.36M
3
BPMC
Blueprint Medicines
BPMC
+$7.73M
4
FBRX icon
Forte Biosciences
FBRX
+$7.25M
5
VIR icon
Vir Biotechnology
VIR
+$7.08M

Top Sells

Rank Stock Value
1
TARS icon
Tarsus Pharmaceuticals
TARS
+$19.2M
2
ONC
BeOne Medicines Ltd
ONC
+$18M
3
SLNO
Soleno Therapeutics
SLNO
+$11.5M
4
RCUS icon
Arcus Biosciences
RCUS
+$5.97M
5
TECX
Tectonic Therapeutic
TECX
+$5.28M

Sector Composition

Rank Sector Weight
1 Healthcare 47.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VERU icon
126
Veru
VERU
$36M
$615K 0.08%
94,524
-114
-0.1% -$846
CRBP icon
127
Corbus Pharmaceuticals
CRBP
$166M
$607K 0.08%
51,431
-233,284
-82% -$3.91M
ITOS
128
DELISTED
iTeos Therapeutics
ITOS
$604K 0.08%
78,585
+11
+0% +$95
SANA icon
129
Sana Biotechnology
SANA
$871M
$595K 0.08%
+365,000
New +$1.09M
OLMA icon
130
Olema Pharmaceuticals
OLMA
$1B
$536K 0.07%
91,994
-6
-0% -$60
ABOS icon
131
Acumen Pharmaceuticals
ABOS
$155M
$457K 0.06%
265,769
-666
-0.2% -$1.6K
DFTX
132
Definium Therapeutics
DFTX
$5.78B
$436K 0.06%
62,691
+210
+0.3% +$1.45K
SPRB
133
Spruce Biosciences
SPRB
$118M
$420K 0.06%
+13,333
New +$489K
TVTX icon
134
Travere Therapeutics
TVTX
$5.2B
$394K 0.05%
+22,600
New +$400K
ELEV
135
DELISTED
Elevation Oncology
ELEV
$388K 0.05%
690,050
-39
-0% -$23
CMMB
136
Chemomab Therapeutics
CMMB
$11.4M
$386K 0.05%
53,263
-85
-0.2% -$537
ABEO icon
137
CALL
Abeona Therapeutics
ABEO
$366M
$362K 0.05%
+65,000
New +$400K
CATX icon
138
Perspective Therapeutics
CATX
$332M
$345K 0.05%
+108,300
New +$884K
CATX icon
139
PUT
Perspective Therapeutics
CATX
$332M
$342K 0.05%
107,200
+30,100
+39% +$246K
FTH
140
Faeth Therapeutics
FTH
$702M
$319K 0.04%
32,498
-2
-0% -$20
VYGR icon
141
Voyager Therapeutics
VYGR
$183M
$316K 0.04%
55,766
-91
-0.2% -$587
CLYM
142
Climb Bio
CLYM
$681M
$315K 0.04%
175,088
-12
-0% -$43
ATXI
143
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
$280K 0.04%
+140,000
New +$284K
KPTI icon
144
Karyopharm Therapeutics
KPTI
$43.5M
$277K 0.04%
27,260
-30
-0.1% -$363
ANEB
145
DELISTED
Anebulo Pharmaceuticals
ANEB
$265K 0.04%
157,720
-142
-0.1% -$234
MGNX icon
146
MacroGenics
MGNX
$235M
$260K 0.04%
80,071
-8
-0% -$29
VTGN icon
147
VistaGen Therapeutics
VTGN
$9.89M
$229K 0.03%
+77,616
New +$218K
LRMR icon
148
Larimar Therapeutics
LRMR
$397M
$226K 0.03%
58,526
-2
-0% -$13
NUVB icon
149
Nuvation Bio
NUVB
$2.2B
$222K 0.03%
83,407
+125
+0.2% +$322
LYRA
150
DELISTED
LYRA THERAPEUTICS INC
LYRA
$218K 0.03%
21,163
+26
+0.1% +$286
4 5
6
7 8

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Ikarian Capital held 212 positions worth $735M, up 2.5% from $717M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Ikarian Capital deployed $54.1M of net new capital in Q4 2024, opening 67 new positions and adding to 34 existing holdings. Its largest new stake was Scholar Rock: 357,185 shares worth $15.4M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 45% a quarter earlier.

On the sell side, the largest reduction was Tarsus Pharmaceuticals, an estimated $19.2M trimmed.

  • Ikarian Capital's largest Q4 2024 buy was Scholar Rock: 357,185 shares worth $15.4M.
  • Ikarian Capital added most to Blueprint Medicines in Q4 2024, an estimated $7.73M increase.
  • Ikarian Capital's biggest Q4 2024 reduction was Tarsus Pharmaceuticals, cutting an estimated $19.2M.
  • Ikarian Capital fully exited BeOne Medicines Ltd in Q4 2024, selling an estimated $18M.
  • Ikarian Capital's ten largest holdings make up 42% of its $735M portfolio in Q4 2024.
  • Ikarian Capital opened 67 new positions and closed 41 in Q4 2024.
  • Ikarian Capital's portfolio value rose 2.5% quarter-over-quarter to $735M.

Based on Ikarian Capital's 13F filing for Q4 2024, filed 14 Feb 2025.